A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

Adalimumab Clinical Trial

Official title:
A Randomized, Single-blind, Single-dose, 2-arm, Parallel-group Study to Determine the Pharmacokinetic Comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 mL (ABP 501-LCF) in Healthy Adult Subjects

Status Completed

Clinical Trial Summary

To determine the pharmacokinetic (PK) comparability of ABP 501 40 mg/0.4 mL (ABP 501-HCF) compared to ABP 501 40 mg/0.8 mL (ABP 501-LCF) following single-dose subcutaneous (SC) injection, as assessed principally by area under the serum concentration-time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and maximum observed serum concentration (Cmax) in healthy adult participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adalimumab

Clinical Trial Details

NCT number	NCT05909852
Study type	Interventional
Source	Amgen
Contact
Status	Completed
Phase	Phase 1
Start date	July 23, 2021
Completion date	November 24, 2021

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02533375` - Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)	Phase 3
Recruiting	`NCT04300686` - A Pilot Study in Severe Patients With Takayasu Arteritis.	Phase 4
Recruiting	`NCT05590416` - A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease
Recruiting	`NCT05155592` - Reduction or Discontinuation of TNF-α Inhibitor in Non-infectious Uveitis Patients	Phase 2
Recruiting	`NCT05015335` - The Efficacy and Safety of Adalimumab in Non-infectious Anterior Pediatric Uveitis With Peripheral Vascular Leakage	Phase 4